Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic Retinopathy: A Systematic Review and Meta-Analysis

Table 3

Potential publication bias by Egger’s and Begg’s tests.

Variables	Begg’s		Egger’s
BCVA
One month	1.23	0.22	10.17	0.07
Three months	−0.24	0.81	4.27	0.47
Overall	0.64	0.52	7.61	0.05
CMT
One month	−0.15	0.88	−5.28	0.46
Overall	−0.60	0.54	1.70	0.12
Complication
IOP	0.90	0.37	0.17	0.79
Inflammation	−1.15	0.25	−0.65	0.06
Cornea abnormalities	16.39	0.37	−3.91	0.05
Overall	0.15	0.88	−0.57	0.05
Quality of life
Social	0.25	0.81	4.77	<0.001
Mental	0.00	0.99	10.51	0.001
Self-care	−0.74	0.45	7.80	0.014
Mobility	1.24	0.22	14.18	<0.001
Overall	0.37	0.71	5.90	<0.001

BCVA, best corrected visual acuity; CMT, central macular thickness; IOP, intraocular pressure.